D745 + D759 + D150

**D745 + D759 + D150** is an investigational combination therapy currently studied for the treatment of type 2 diabetes. The regimen consists of three separate agents, referred to by their code names (D745, D759, D150), administered together. Clinical trials have assessed its efficacy, safety, and pharmacokinetics, including HbA1c reduction for patients whose glucose levels are inadequately controlled by two-drug regimens (D150 plus D759). The mechanism of action and modalities of each component are not explicitly described in public trial registries, but the drug is developed as a pharmaceutical therapy for glycemic control in type 2 diabetes patients, indicating a likely small molecule or biologic anti-diabetic agent profile[1][5][7].